←
KRAS Kickers5,185 posts
KRAS Kickers avatar

KRAS Kickers

@KRASKickers

#KRAS 🎯cancer patient group for reliable Knowledge Research Advocacy & Survivorship. Survival of the strategic. #KickCancersKRAS - 🚫 #KRASholes

◷ Joined February 2020▧ 595 Photos and videos
Dr. Shubham Pant avatar
⟳ KRAS Kickers retweeted
Dr. Shubham Pant@DrShubhamPant·Nov 17

Loved chairing the RAS-Altered Cancers “Hot Seat” session at #CFS2026. 🎯 Think Family Feud for oncology: @gotoPER & organizers used AI to answer pre-submitted audience questions, and the room debated the burning issues in RAS-driven GI, lung cancers. CME needs more of this!

Post attachmentPost attachment
AACR avatar
⟳ KRAS Kickers retweeted
AACR@AACR·8h

Ryan Corcoran, #ENASymp26 cochair for AACR, is in Barcelona today to convene the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. We thank Dr. Corcoran and his cochairs, Tim Greten and Elena Garralda, for developing an outstanding program. @EORTC @theNCI

Post attachmentPost attachment
KRAS Kickers avatar
KRAS Kickers@KRASKickers·4h

Hope lies in the Long View. Hope lies in believing there are solutions to complicated problems. Hope lies in trusting that those with smart minds and kind hearts can come together. Thank you, @RevMedicines for caring for the many patients with RAS-addicted cancers.

This Lung Cancer and Pancreatic Cancer Awareness Month, share hope for those affected by RAS-addicted cancers. For each message submitted this month, Revolution Medicines will donate $50 to @KRASKickers, up to $30,000. Add yours: revmed.com/revolution-ras/?u…

Post attachment
KRAS Kickers avatar
KRAS Kickers@KRASKickers·5h

SHARE HOPE. A few words of encouragement can make a real difference! Revolution Medicines is donating $50 to KRAS Kickers for every message of hope submitted, up to $30,000. Share a few words of encouragement for people impacted by RAS cancers. It takes just a moment, and @RevMedicines contributes $50 to KRAS Kickers for every submitted message, up to $30,000. revmed.com/revolution-ras/?u… Every message matters. Every share expands our reach. Every contribution supports our mission.

Post attachment
KRAS Kickers avatar
KRAS Kickers@KRASKickers·6h

TARGET-D 201 expansion to Spain and France (already in US & Australia) A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy & W/ Cetuximab, in Patients W/ Metastatic KRAS G12D-Mutated Pancreatic Cancer Opened June 26 180 ps NCT07644559 VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors - Oct 15 cancernetwork.com/view/vs-73… Trial post and links facebook.com/permalink.php?s…

Post attachment
Erasca avatar
⟳ KRAS Kickers retweeted
Erasca@Erasca·23h

We’re pleased to announce that we entered into a clinical collaboration with @bmsnews to evaluate the combination of ERAS-0015 and navlimetostat, an investigational PRMT5 inhibitor, in patients with MTAP-deleted pancreatic cancer. Learn more: investors.erasca.com/news-re…

0:19
Anirban Maitra avatar
⟳ KRAS Kickers retweeted
Anirban Maitra@Aiims1742·Nov 16

Daraxonrasib is now approved in the second line and beyond in metastatic #PancreaticCancer in the European Union. Good news for patients across the pond! @RevMedicines @KRASKickers revmed.com/media/news/13736/…

OncLive.com avatar
⟳ KRAS Kickers retweeted
OncLive.com@OncLive·Nov 16

💥 More updates in the evolving RAS space! This time an @FDA fast track designation for onvansertib in KRAS- or NRAS-mutated mCRC in the frontline Full details ➡️: onclive.com/view/onvansertib… #oncology #crcsm

KRAS Kickers avatar
KRAS Kickers@KRASKickers·Nov 16

Trial expansion 440 to 570 patients 5 arms to 7 arms 6 new locations (in China) A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation NCT06385925

KRAS Kickers in the house for ASCO #GI26 to see Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. Presenter: Siqing Fu, M.D., Ph.D. @MDAndersonNews asco.org/abstracts-presentat… ASCO 25 asco.org/abstracts-presentat… Trial NCT06385925 expanded in Dec from 2 to 5 arms; from 150 to 440 pts

Post attachment
Owen Gregorian avatar
⟳ KRAS Kickers retweeted
Owen Gregorian@OwenGregorian·Nov 9

Pancreatic Cancer Drug RASONQUE Doubled Survival: Greece Offers It Free Before EU Acts | James Whitaker, Techtimes Greek Health Minister Adonis Georgiadis announced to Greek media this week that the first patients in Greece have begun receiving RASONQUE — the brand name for daraxonrasib, a targeted cancer drug which the FDA approved August 26, 2026 — entirely free of charge through the country's national health infrastructure. The announcement makes Greece one of a handful of countries outside the United States to offer the treatment, and the first to do so at zero cost to eligible patients before the European Commission has formally completed its authorization process. The drug targets a mutation found in more than 90 percent of pancreatic cancers — a gene called KRAS that researchers have been trying, and failing, to block directly for over four decades. In a Phase 3 trial of 500 patients, it more than doubled median survival compared with standard chemotherapy: 13.2 months versus 6.7 months, with a 60 percent reduction in the risk of death. For a cancer in which stage IV patients have historically had a five-year survival rate of about one percent, that number carries the weight of a field-redefining shift. The 40-Year Barrier That Just Fell To appreciate what Greece's move represents, it helps to understand the science behind the drug — and why it took so long to exist. The KRAS gene was first characterized as a molecular switch in 1979 and linked to human cancers by 1982. Within a decade, researchers had established that KRAS mutations drive more than 90 percent of pancreatic cancers, roughly 34 percent of non-small cell lung cancers, and around 45 percent of colorectal cancers. RAS mutations more broadly appear in approximately 30 percent of all human cancers, making the RAS protein family the single most common oncogenic driver in human biology. For nearly four decades, however, every attempt to block the protein directly failed. Its surface is smooth, offering no obvious pocket for a drug molecule to bind. By the 2000s, the field had arrived at a consensus — not as a description of the available tools, but as a presumed biological fact: KRAS was undruggable. Grant applications stopped proposing direct inhibition. Careers pivoted to downstream targets in the signaling cascade. An entire generation of oncologists was trained with the assumption that any drug targeting RAS directly would never be developed. What changed, ultimately, was the question being asked. Earlier KRAS inhibitors — sotorasib, approved in 2021, and adagrasib, approved in 2022 — took the conventional approach of binding to the protein when it was in its inactive, GDP-bound ("off") state. That worked for one specific mutation, called G12C, which creates a reactive pocket in the inactive form. The result was effective for the roughly 13 percent of non-small cell lung cancer patients who carry that mutation. But G12C is rare in pancreatic cancer, where the dominant mutations are G12D and G12V — variants that have no equivalent pocket in the inactive state. Revolution Medicines made the breakthrough by asking a different question: what if you targeted the protein when it was on — in its active, GTP-bound state, the form that actually drives tumor growth? In the active state, KRAS adopts a conformation that creates a binding site invisible in the inactive form. Daraxonrasib exploits this. The drug does not bind RAS directly in a conventional sense; instead, it first latches onto a chaperone protein called cyclophilin A that is already present inside the cell. The daraxonrasib-cyclophilin A binary complex then docks onto the active RAS protein, forming a three-part "tri-complex" that physically blocks the downstream effectors RAS needs to send its growth signals. Because the active state is shared across multiple RAS mutation subtypes — G12D, G12V, G12C, and others — the same molecule works against all of them simultaneously. Hence the clinical term: multi-selective RAS(ON) inhibitor. This mechanistic insight — that the "undruggable" label was a failure of imagination about which conformation to target, not a true property of the molecule — is the scientific revolution behind the clinical numbers. What the Clinical Trial Showed The FDA's approval was based on data from RASolute 302, a randomized, open-label Phase 3 trial that enrolled 500 patients with metastatic pancreatic adenocarcinoma — the most common form of pancreatic cancer — that had progressed after at least one prior line of systemic therapy. Half received daraxonrasib at 300 mg orally once daily; the other half received investigator's choice of standard chemotherapy. The results, documented in the FDA prescribing information, were presented at the American Society of Clinical Oncology annual meeting in Chicago in May 2026 and simultaneously published in the New England Journal of Medicine. By the grim benchmarks of this disease, they were striking: - Median overall survival: 13.2 months (daraxonrasib) versus 6.7 months (chemotherapy), hazard ratio 0.40, a 60 percent reduction in the risk of death (p < 0.0001) - Median progression-free survival: 7.2 months versus 3.6 months (HR = 0.49, p < 0.0001) - Tumor response: 30 percent of patients on daraxonrasib experienced measurable tumor shrinkage, compared with 11 percent on chemotherapy, per the ONS drug reference - 12-month survival: 53.2 percent of daraxonrasib patients were alive at one year, versus 17.3 percent in the chemotherapy group Quality-of-life outcomes also favored the new treatment. The median time to deterioration in global health status — a measure of when patients began to feel meaningfully worse — was 5.7 months with daraxonrasib versus 2.6 months with standard chemotherapy. The drug's safety profile compared favorably to chemotherapy. The most common side effects are dermatologic: rash, dry skin, and paronychia (inflamed, raw fingertips) typically emerge within about two weeks of starting treatment. Diarrhea and stomatitis (mouth sores) are also common, as are fatigue and decreased appetite. Serious but rare events include gastrointestinal perforation and interstitial lung disease; standard management protocols — topical corticosteroids from the start of treatment, prophylactic doxycycline or minocycline, prompt antidiarrheals — are described in the prescribing information. The FDA granted the drug Breakthrough Therapy designation, Orphan Drug designation, and Priority Review, and completed its review approximately 6.5 months ahead of the FDA's goal date under its Commissioner's National Priority Voucher pilot program. How Greece Got Here Early The path to access in Greece runs through a formal pre-authorization mechanism administered by the country's national health organization, known by its Greek acronym EOPYY. Under the process, a patient's oncologist prepares an electronic file documenting the patient's treatment history, current clinical status, and a recent CT scan. The file is submitted electronically to EOPYY, which forwards it to a panel of three independent oncologists for review. If approved, authorization is transmitted electronically to the patient's national social security number (AMKA). The Institute of Pharmaceutical Research and Technology (IFET) — a subsidiary of Greece's National Medicines Agency — then procures the drug and supplies it to the treating oncologist for administration. The critical element: the treatment is provided entirely at no cost to eligible patients. As Professor Grigoris Tsiotos of the Mayo Clinic and president of the Hellenic Pancreas Institute, who has been closely involved in advising on pancreatic cancer care in Greece, Tsiotos told Greek media that by the time Georgiadis made his announcement, Greek health authorities had already approved approximately nine or ten patient applications. Greece has moved on two separate regulatory tracks. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending EU marketing authorization on October 15, 2026 — but that opinion still requires formal ratification by the European Commission before the drug can be routinely prescribed across EU member states. The timeline for the Commission's final decision has not been announced. Greece's early-access mechanism allowed the country to begin treating patients in the gap between the CHMP positive opinion and the eventual Commission decision. The EMA's recommended indication closely mirrors the FDA's: adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. One difference: the FDA label also covers patients who are not candidates for multiagent systemic therapy — a provision absent from the CHMP recommendation, per OncLive's coverage of CHMP. For context: the US wholesale acquisition cost of RASONQUE is $39,800 per month at the recommended dosage. Greece's provision of the drug free of charge to eligible patients reflects a healthcare model in which public access, not commercial pricing, governs availability during the pre-authorization window. Why This Disease Makes the Numbers Matter Pancreatic adenocarcinoma accounts for an estimated 500,000 new diagnoses worldwide each year. In the United States alone, approximately 67,000 new cases are expected in 2026, with roughly 52,740 deaths projected — meaning the disease will kill nearly as many Americans as it diagnoses, in the same year. Three factors conspire to make it so deadly. The disease progresses faster than cancers like breast or colorectal cancer. Its symptoms — abdominal or back pain, sudden-onset diabetes, unexplained weight loss, greasy stools — are non-specific and often appear only after the cancer has spread, leading to late diagnosis. And the tumor frequently invades the major blood vessels surrounding the pancreas before it is detected, making surgery impossible in the majority of cases. For patients with metastatic disease who have already received first-line treatment, the landscape before RASONQUE was stark: median survival measured in months, response rates in the single digits, and no targeted therapy approved for a cancer driven in nine out of ten cases by the very mutation the field had spent four decades calling untreatable. What Comes Next RASONQUE's current approval — both in the US and under EMA's recommendation — is for previously treated metastatic pancreatic cancer. The scope is likely to expand. In September 2026, the FDA granted Breakthrough Therapy designation to daraxonrasib in combination with chemotherapy as a potential first-line treatment for metastatic pancreatic cancer — a signal that regulators are open to evaluating it in earlier treatment settings. The ongoing RASolute 303 trial is studying daraxonrasib with or without chemotherapy as a frontline option. Revolution Medicines is also pursuing approvals beyond pancreatic cancer. A Phase 1/2 trial reported promising data in non-small cell lung cancer, where RAS mutations are similarly prevalent, and Phase 3 trials in NSCLC are underway. The company is additionally investigating daraxonrasib in colorectal cancer. There is a broader scientific implication, too. Resistance to daraxonrasib — as with most targeted cancer therapies — is expected to emerge over time, and preclinical work suggests combination strategies may help delay it. But the breakthrough's significance extends beyond this single drug. By demonstrating that RAS proteins can be directly inhibited with meaningful clinical benefit — by finding the right conformation to attack — the field has established a proof of concept applicable to other historically resistant targets. Researchers at institutions including the University of Pennsylvania's Abramson Cancer Center have noted that proving an "undruggable" target is in fact drugable raises the possibility of doing so again with others. For the Greek patients now receiving the pill at no charge, the wider implications are secondary. What matters is that a disease that offered little beyond months of toxic chemotherapy now has a targeted treatment that more than doubled median survival — and that their government moved quickly enough for them not to have to wait. techtimes.com/articles/33021…

Post attachment
CrozrX avatar
⟳ KRAS Kickers retweeted
CrozrX@CrozrX·Nov 10

Jorge Luis Borges wrote that every writer creates his own precursors. A truly original work does not join history, it rearranges history so that every prior discovery now looks like it existed only to announce its coming. Few scientists embody that thought as profoundly as Robert Weinberg. His pioneering contributions helped establish the molecular foundations of modern oncology, from the identification of the first human oncogene, RAS, and the characterization of HER2/neu, to the isolation of the first tumor suppressor gene, RB. His subsequent work on telomerase and the experimental transformation of normal human cells helped illuminate how multiple alterations cooperate to produce malignancy. Yet his scientific journey evolved far beyond the genes that initiate cancer. Through seminal work on epithelial–mesenchymal transition, cancer stem cells, cellular plasticity, and metastasis, his laboratory helped reveal how malignant cells acquire new identities, adapt to changing environments, resist treatment, and colonize distant tissues. And with Douglas Hanahan, the Hallmarks of Cancer offered something even more consequential: an intellectual architecture through which decades of seemingly disparate discoveries could be understood as interconnected dimensions of the same disease. Beyond recognizing individual patterns of malignancy, they helped reveal the patterns connecting them. This is where Borges's observation becomes especially meaningful. Weinberg did not simply contribute discoveries to the history of cancer biology. His work helped reorganize that history, changing how generations of scientists interpret what came before and envision what might come next. As his laboratory prepares to close, its legacy reaches far beyond the discoveries made within its walls. It lives in generations of scientists who carried its curiosity and rigor into the world, in therapeutic advances built upon its scientific foundations, and in patients whose lives have been changed by discoveries that once existed only as questions in a laboratory. That influence will continue reaching patients and families for generations to come. The laboratory may close. The intellectual architecture continues to evolve. I even proposed 🔸️BOBRASIB🔸️ as a name for Verastem's KRAS G12D inhibitor, VS-7375, in tribute to Robert Weinberg, one of the company's founders and scientific advisors, whose pioneering work helped establish the foundations of modern RAS biology. 📎 lnkd.in/p/gbmyevRV @kochinstitute @WhiteheadInst @broadinstitute @SenduraiMani @Ludwig_Cancer @MIT @RonDePinho

Post attachmentPost attachment
Stephen V Liu, MD avatar
⟳ KRAS Kickers retweeted
Stephen V Liu, MD@StephenVLiu·Nov 10

First #ESMO26 highlights episode of the @IASLC podcast Lung Cancer Considered features Drs. @sands_jacob @DrJNaidoo and @FSkoulidis touching on DeLLphi-305, Krascendo 1, and MOIO among others. Very impactful @myESMO meeting for lung cancer! iaslc.org/iaslc-news/lung-ca…